Patents by Inventor Malcolm Philip Young
Malcolm Philip Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330058Abstract: There is described the use of an agent in the manufacture of a therapy for the treatment or alleviation of a senescence-associated disease, disorder or effect, wherein the agent is selected from one or more of A42548, A425619, alpha lipoic acid, apigenin, Artemisinin, BML-288, BTBHQ, EGCG, fluphenazine dihydrochloride, honokiol, LE300, magnolol, niclosamide, nicotinamide, nordihydroguaiaretic acid, quercetin, resveratrol and a mitochondrial uncoupler. There is also described the use of a mitochondrial uncoupler as an agent for the treatment of a senescence-associated disorder; and the use of an uncoupler in association with a senolytic agent.Type: ApplicationFiled: September 8, 2021Publication date: October 19, 2023Applicant: NUCHIDO LIMITEDInventors: Nichola Jane Conlon, Malcolm Philip Young
-
Publication number: 20210267870Abstract: There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACT1 peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, ?-lapachone, ?-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (?)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-?-glycyrrhetinic acid, 18-?-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (Na AD), nicotinic acid mononucleotide (Na MN), parsley (Petroselinium crispum), phenylephrine, pokeweedType: ApplicationFiled: July 10, 2019Publication date: September 2, 2021Applicant: NUCHIDO LIMITEDInventors: Nichola Jane Conlon, Malcolm Philip Young
-
Publication number: 20210015788Abstract: There is described a composition comprising an effective amount of a combination of two or more components selected from a NAD precursor; a NAMPT upregulator; a NQO1 upregulator and a NNMT (nicotinamide N-methyltransferase) downregulator.Type: ApplicationFiled: March 13, 2019Publication date: January 21, 2021Applicant: NUCHIDO LIMITEDInventors: Nichola Jane Conlon, Malcolm Philip Young
-
Publication number: 20210015842Abstract: There is described a method of method of augmentation of plasma which comprises reducing the activity of NAD catabolic and excretory pathway enzymes and/or promoting NAD anabolic pathways, by incorporating into the plasma exogenous NAD or a NAD promoter; or a combination thereof.Type: ApplicationFiled: March 13, 2019Publication date: January 21, 2021Applicant: NUCHIDO LIMITEDInventors: Nichola Jane Conlon, Malcolm Philip Young
-
Publication number: 20180042891Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NF?B), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.Type: ApplicationFiled: October 3, 2017Publication date: February 15, 2018Applicant: e-Therapeutics plcInventors: Malcolm Philip Young, Philip McKeown
-
Publication number: 20150093438Abstract: There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub-analgesic amount is from about 60 to 80 mg, of tramadol or a salt thereof.Type: ApplicationFiled: May 3, 2013Publication date: April 2, 2015Inventors: Malcolm Philip Young, Philip McKeown
-
Publication number: 20150072020Abstract: There is described a method of treating cancer in a patient wherein the method comprises the administration of dexanabinol, or a derivative thereof, in an amount of from about 2 mg/kg to about 30 mg/kg, based on the weight of the patient.Type: ApplicationFiled: April 26, 2013Publication date: March 12, 2015Applicant: E-THERAUPEUTICS PLCInventors: Malcolm Philip Young, Philip McKeown
-
Patent number: 8614179Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.Type: GrantFiled: July 17, 2009Date of Patent: December 24, 2013Assignee: E-Therapeutics PLCInventors: Malcolm Philip Young, Catherine Mary Thomas
-
Publication number: 20130296437Abstract: There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof.Type: ApplicationFiled: March 5, 2013Publication date: November 7, 2013Applicant: e-Therapeutics plcInventors: Malcolm Philip Young, Philip McKeown
-
Publication number: 20120190735Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.Type: ApplicationFiled: September 10, 2010Publication date: July 26, 2012Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Philip McKeown
-
Publication number: 20110257078Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.Type: ApplicationFiled: July 17, 2009Publication date: October 20, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas
-
Publication number: 20110212173Abstract: There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto.Type: ApplicationFiled: June 17, 2009Publication date: September 1, 2011Applicant: e-Therapeutics PleInventors: Malcolm Philip Young, Olusola Clement Idowu, Philip McKeown
-
Publication number: 20110039906Abstract: There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.Type: ApplicationFiled: July 18, 2008Publication date: February 17, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20110033376Abstract: There is described dexanabinol, or a derivative thereof, for the treatment of melanoma. There is also described a method of treating a patient suffering from melanoma.Type: ApplicationFiled: July 4, 2008Publication date: February 10, 2011Inventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20110034480Abstract: There is described a pharmaceutical composition comprising a therapeutically effective amount of cetirizine, or a pharmaceutically acceptable derivative thereof, and a therapeutically effective amount of one or more compounds selected from the group consisting of a non beta-2-adrenoreceptor agonist; a beta-2-adrenoreceptor agonist and an anti-inflammatory agent; in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.Type: ApplicationFiled: October 3, 2008Publication date: February 10, 2011Inventors: Malcolm Philip Young, Roy Drucker
-
Publication number: 20110020217Abstract: There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.Type: ApplicationFiled: October 10, 2008Publication date: January 27, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu
-
Publication number: 20100144626Abstract: There is described an imidazole for the treatment of an infection caused or contributed to by microorganisms resistant to antibiotics. There is also described a method of treating a patient suffering from an infection caused or contributed to by microorganisms resistant to antibiotics, said method comprising the step of administering an effective amount of an imidazole.Type: ApplicationFiled: November 15, 2007Publication date: June 10, 2010Inventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20090005443Abstract: There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof, for the treatment or alleviation of depression. There is also described a method of treating a patient suffering from depression.Type: ApplicationFiled: June 20, 2008Publication date: January 1, 2009Inventors: Malcolm Philip Young, Catherine Mary Yates, Olusola Clement Idowu, Julie Anne Charlton